-
Gene Editing Tool in Ongoing Sickle Cell Trial of BIVV003 Supported by Early Study
A proof-of-concept study supports Sangamo’s ZFN gene editing technology used with the cell therapy BIVV003, now in a Phase 1/2 trial in severe SCD patients. Click here to learn more.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.